PD05-03: Impact of Quantitative Measurement of HER2, HER3, HER4, EGFR, ER and PTEN Protein Expression on Benefit to Adjuvant Trastuzumab in Early-Stage HER2+ Breast Cancer Patients in NCCTG N9831.
EA Perez, KV Ballman, MM Reinholz, A. C. Dueck et autres
us (code pays fourni par la source)